Microbot Medical (NASDAQ:MBOT) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Microbot Medical (NASDAQ:MBOT) from a strong sell rating to a sell rating in a report issued on Saturday.

Several other brokerages have also commented on MBOT. Weiss Ratings restated a “sell (d-)” rating on shares of Microbot Medical in a research note on Friday, April 10th. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Microbot Medical in a research note on Tuesday, April 14th. Finally, B. Riley Financial started coverage on shares of Microbot Medical in a research note on Tuesday, February 10th. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.50.

Microbot Medical Price Performance

Shares of NASDAQ:MBOT opened at $1.85 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 23.16 and a current ratio of 22.59. The company has a market cap of $124.26 million, a PE ratio of -7.12 and a beta of 1.06. Microbot Medical has a 52 week low of $1.60 and a 52 week high of $4.67. The firm has a 50 day simple moving average of $2.36 and a 200 day simple moving average of $2.21.

Microbot Medical (NASDAQ:MBOT) last released its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. The company had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.30 million. As a group, research analysts expect that Microbot Medical will post -0.34 earnings per share for the current year.

Institutional Trading of Microbot Medical

A number of hedge funds have recently bought and sold shares of MBOT. CIBC Private Wealth Group LLC lifted its holdings in shares of Microbot Medical by 137.6% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,454,000 shares of the biotechnology company’s stock worth $4,435,000 after acquiring an additional 842,000 shares during the period. Heights Capital Management Inc. bought a new position in shares of Microbot Medical during the 3rd quarter worth about $2,693,000. DNB Asset Management AS lifted its holdings in shares of Microbot Medical by 26.4% during the 3rd quarter. DNB Asset Management AS now owns 243,629 shares of the biotechnology company’s stock worth $743,000 after acquiring an additional 50,843 shares during the period. Cornerstone Advisory LLC bought a new position in shares of Microbot Medical during the 3rd quarter worth about $30,000. Finally, Beacon Capital Management LLC lifted its holdings in shares of Microbot Medical by 37.5% during the 3rd quarter. Beacon Capital Management LLC now owns 22,000 shares of the biotechnology company’s stock worth $67,000 after acquiring an additional 6,000 shares during the period. 16.30% of the stock is owned by institutional investors.

About Microbot Medical

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.